The Claim

Dasatinib plus quercetin has no effect on bone resorption marker CTx at 20 weeks in postmenopausal women.

Source: Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
67score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In postmenopausal women, a combination of dasatinib and quercetin does not lower levels of the bone resorption marker CTx after 20 weeks of treatment.

See the scientific wording

Dasatinib plus quercetin does not reduce the bone resorption marker CTx at 20 weeks in postmenopausal women overall, contradicting preclinical expectations that senolytics would suppress bone breakdown.

Why this might work

Damaged cells in bone release a protein that blocks bone building. When these damaged cells are removed, the block is lifted, allowing bone to form faster. As bone forms, the body naturally reduces bone breakdown.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial

    In most postmenopausal women, the drug combo didn't slow bone loss, but in women with lots of old, damaged cells, it actually helped bones get stronger and reduced bone breakdown — so the treatment works for some, just not everyone.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.